Our Company
Our Company

Kye Pharmaceuticals

From registration to commercialization, the Kye team creatively addresses the challenges of the pharmaceutical environment to bring important new medicines to Canadians.

Our Company

Our Leadership TeamBoard of DirectorsKye in the Community
ProductsPress ReleasesPartneringCareersContact
En
Fr
Home
Our Company

Kye Pharmaceuticals

From registration to commercialization, the Kye team creatively addresses the challenges of the pharmaceutical environment to bring important new medicines to Canadians.

Our Company

Our Leadership TeamBoard of DirectorsKye in the Community
ProductsPress ReleasesPartneringCareersContact
Featured Post

Kye Pharmaceuticals Announces the Availability of Dyanavel® XR Tablets Across Canada for the Treatment of ADHD

June 8, 2026
Read More

August 18, 2020

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada

Read More

July 9, 2020

Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada

Read More
Previous
Follow us on LinkedIn!
Kye Pharmaceuticals © 2025. All Rights Reserved.  |  Web Design by Aquí.
ContactPrivacy PolicyTerms of Use
Kye Pharmaceuticals © 2025. All Rights Reserved.  Web Design by Aquí.